Use this form to manage your e-mail subscriptions.
Looking for your online application?
To ensure the security of your profile information, please re-enter your password.
Don’t have an account? Register here.
Register to get full access to our articles and reports, including those by the
McKinsey Quarterly and the McKinsey Global Institute, and to subscribe to
our newsletters and e-mail alerts.
Sorry, something went wrong and we cannot reset your password right now. Please try again later.
Please enter the e-mail address you use to sign into your account.
We have e-mailed instructions on how to reset your password.
The McKinsey Quarterly, our business journal, includes many articles on healthcare-related topics.
June 2013—Most Chinese physicians participate actively in social media, and many hospitals have picked up on the trend—but drug manufacturers are just beginning to do so.more
August 2012—After years of seeing value destroyed by R&D excesses, biopharmaceutical companies can gain healthier returns—but only if they recognize several new imperatives.more
August 2012—The sector can restore lost value by focusing intently on manufacturing innovation.more
April 2012—Global pharma companies are missing a chance to serve Brazil’s increasingly prosperous and growing middle class.more
December 2011—Lower profit margins suggest a need for new business models.more
September 2011—A daunting array of financial and operational barriers is holding back growth. What can be done?more
May 2011—The highest-performing labs use the best talent-management practices. That’s no coincidence.more
The PMP practice has published several compendia—compilations of insights on important trends and issues.
Personalized medicine is now poised for rapid growth because of recent scientific advances. With the right strategies, pharmacos, biotechs, and diagnostic companies could capture many new opportunities in this surging field.
Emerging markets offer attractive opportunities for growth, but pharma companies need to navigate the intricacies of individual markets and develop tailored capabilities and commercial models to tackle the challenges.
China’s healthcare sector continues to develop at an astonishing rate, but challenges remain. McKinsey’s Healthcare Practice in China has published a new report which offers a diversity of perspectives on this substantial, complex and important domain. A selection of articles are published on the McKinsey China Healthcare page.
Highlights specific opportunities for operations to create significant value upside for pharmacos and emphasizes the role of the executive suite in enabling this value creation
Discusses how pharmaceutical companies will need to adjust their traditional sales models to suit the evolving healthcare landscape
Recent years have seen a collapse in the industry’s R&D productivity. Regaining trust by delivering life-changing new drugs is still an achievable goal, but it will require discipline, creativity, and luck in equal measure.
Reviews our major recommendations for improving pharmaceutical operations and increasing client capabilities.
Our white papers examine a single issue in depth, providing clients with a rigorous fact base, objective perspectives, and new insights into pressing industry issues.
Although the future of biosimilars is still uncertain, several developments give reason to believe that they are here to stay and that some companies will eventually make reasonable returns on their biosimilar programs. However, the range of outcomes is still wide, and depends heavily on which stakeholders make the first moves.
The branded pharmaceutical industry is performing at a level of productivity that is lower than what modern technology would allow it. Now Japan is at the leading edge of what may be a better way: e-detailing.
October 2012—The promise of global standards in healthcare and an opportunity for innovation.
With increased data transparency, winning launches will require Pharma to harness new sources of information to develop superior real-time insights, and rapidly operationalise decisions based on these insights.
Clinical pathways will have a long term effect on the practice of oncology. Pharmaceutical companies can realize value if they understand how pathway solutions are developed and use these insights as an input to their own R&D and commercialization strategies.
Real-world data, collected at the point of care, is beginning to create new opportunities throughout the healthcare business system.
As price pressures increase, medical device makers can use Design to Value to control costs and deliver value.
The US government recently updated legislation related to biosimilars. Payors, originators, and biosimilar companies must be aware of its implications, as well as areas that remain ambiguous.
Multinational corporations have traditionally had little success when entering in-bound alliances with Japanese pharmaceutical companies. But new circumstances make it the ideal time to pursue such deals.
New reimbursement guidelines make it difficult for pharmaceutical companies to earn profits on recently approved products. A cross-functional strategy, involving both R&D and commercial functions, can help them maximize value.
By developing robust clinical strategies early in a drug's lifecycle, pharmaceutical companies can generate data that will build the clinical profile of the brand over its lifetime.
By drawing on examples from other industries, pharmaceutical companies can take an entrepreneurial approach that helps key account managers create innovative solutions.
The Indian pharmaceutical market is growing rapidly. Businesses that are aware of trends and the changing nature of opportunities will be well positioned to capture value.
We publish selected articles in industry magazines including In Vivo, The RPM Report, Nature Reviews Drug Discovery, Pharmaceutical Manufacturing, Pharmaceutical Executive, PharmaVoice, and others.
June 2012—Device companies are trying to figure out successful formulas to sell in emerging markets. Instead of reinventing the wheel, they can leverage several approaches that have worked well in other industries.
January 2012—This article describes why various healthcare stakeholders are using social media and provides a perspective on how pharmaceutical companies can make the most of it.
March 2010—Providers, payors, and regulators are placing new emphasis on comparative efficacy when evaluating medical devices. To succeed in the new environment, companies will need to focus on products that have value over existing therapies.
Required fields are marked with an asterisk (*).
Request a copy of one of our compendia with industry-specific insights in key functional areas or geographies.